Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD (IDEAL)

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00159835
First received: September 8, 2005
Last updated: September 22, 2009
Last verified: May 2007
  Purpose

To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.


Condition Intervention Phase
Cardiovascular Diseases
Drug: atorvastatin
Drug: simvastatin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest

Secondary Outcome Measures:
  • 1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality

Estimated Enrollment: 8600
Study Start Date: February 1999
Estimated Study Completion Date: March 2005
  Eligibility

Ages Eligible for Study:   up to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previous myocardial infarction

Exclusion Criteria:

  • Women who are breast feeding or are pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159835

  Hide Study Locations
Locations
Denmark
Pfizer Investigational Site
Arhus C, Denmark, DK-8000
Pfizer Investigational Site
Copenhagen, Denmark, 2100
Pfizer Investigational Site
Esbjerg, Denmark, 6700
Pfizer Investigational Site
Fredericia, Denmark, 7000
Pfizer Investigational Site
Frederiksberg, Denmark, 2000
Pfizer Investigational Site
Frederikssund, Denmark, 3600
Pfizer Investigational Site
Grena, Denmark, 8500
Pfizer Investigational Site
Helsingoer, Denmark, 3000
Pfizer Investigational Site
Hjorring, Denmark, 9800
Pfizer Investigational Site
Holbak, Denmark, 4300
Pfizer Investigational Site
Holstebro, Denmark, 7500
Pfizer Investigational Site
Hvidovre, Denmark, 2650
Pfizer Investigational Site
Kabenhavn S, Denmark, 2300
Pfizer Investigational Site
Kalundborg, Denmark, 4400
Pfizer Investigational Site
Kobenhavn K, Denmark, 1256
Pfizer Investigational Site
Kobenhavn Nv, Denmark, 2400
Pfizer Investigational Site
Koge, Denmark, 4600
Pfizer Investigational Site
København NV, Denmark, 2400
Pfizer Investigational Site
Middelfart, Denmark, 5500
Pfizer Investigational Site
Naestved, Denmark, 4700
Pfizer Investigational Site
Nykobing F, Denmark, 4800
Pfizer Investigational Site
Odder, Denmark, 8300
Pfizer Investigational Site
Randers, Denmark, 8900
Pfizer Investigational Site
Roskilde, Denmark, 4000
Pfizer Investigational Site
Silkeborg, Denmark, 8600
Pfizer Investigational Site
Skive, Denmark, 7800
Pfizer Investigational Site
Slagelse, Denmark, 4200
Pfizer Investigational Site
Svendborg, Denmark, 5700
Finland
Pfizer Investigational Site
Heinola, Finland, 18100
Pfizer Investigational Site
Helsinki, Finland, 00100
Pfizer Investigational Site
Helsinki, Finland, 00029
Pfizer Investigational Site
Joensuu, Finland, 80210
Pfizer Investigational Site
Jyvaskyla, Finland, 40100
Pfizer Investigational Site
Kerava, Finland, 04200
Pfizer Investigational Site
Kuopio, Finland, 70210
Pfizer Investigational Site
Lahti, Finland, 15110
Pfizer Investigational Site
Lappeenranta, Finland, 53130
Pfizer Investigational Site
Lohja, Finland, 08200
Pfizer Investigational Site
Mikkeli, Finland, 50100
Pfizer Investigational Site
Rauma, Finland, 26100
Pfizer Investigational Site
Salo, Finland, 24130
Pfizer Investigational Site
Siaraalamaki, Finland, 45750
Pfizer Investigational Site
Tammisaari, Finland, 10600
Pfizer Investigational Site
Tampere, Finland, 33520
Pfizer Investigational Site
Vantaa, Finland, 01400
Iceland
Pfizer Investigational Site
Reykjavik, Iceland, 101
Pfizer Investigational Site
Reykjavik, Iceland, 108
Netherlands
Pfizer Investigational Site
's-Hertogenbosch, Netherlands, 5211 NL
Pfizer Investigational Site
Alkmaar, Netherlands, 1815 JD
Pfizer Investigational Site
Amsterdam, Netherlands, 1061 AE
Pfizer Investigational Site
Assen, Netherlands, 9401 RK
Pfizer Investigational Site
Breda, Netherlands, 4818 CK
Pfizer Investigational Site
Capelle Aan Den Ijssel, Netherlands, 2906 ZC
Pfizer Investigational Site
Delft, Netherlands, 2625 AD
Pfizer Investigational Site
Deventer, Netherlands, 7415 CM
Pfizer Investigational Site
EDE, Netherlands, 6716 RP
Pfizer Investigational Site
Eindhoven, Netherlands, 5623 EJ
Pfizer Investigational Site
Enschede, Netherlands, 7511 JX
Pfizer Investigational Site
Goes, Netherlands, 4462 RA
Pfizer Investigational Site
Groningen, Netherlands, 9721 SW
Pfizer Investigational Site
Hoorn, Netherlands, 1624 GM
Pfizer Investigational Site
Nijmegen, Netherlands, 6532 SZ
Pfizer Investigational Site
Oss, Netherlands, NL-5342 BT
Pfizer Investigational Site
Rotterdam, Netherlands, 3045 PM
Pfizer Investigational Site
Tilburg, Netherlands, 5022 GC
Pfizer Investigational Site
Tilurg, Netherlands, 5022 GC
Pfizer Investigational Site
Utrecht, Netherlands, NL-3508-TG
Pfizer Investigational Site
Weert, Netherlands, 6001 BE
Pfizer Investigational Site
Zwijndrecht, Netherlands, 3331 LZ
Pfizer Investigational Site
Zwolle, Netherlands, 8011 JW
Norway
Pfizer Investigational Site
8092 Bodo, Norway, 8092
Pfizer Investigational Site
Alesund, Norway, 6002
Pfizer Investigational Site
Alesund, Norway, 6026
Pfizer Investigational Site
Bergen, Norway, 5009
Pfizer Investigational Site
Bergen, Norway, 5021
Pfizer Investigational Site
Bergen, Norway, 5008
Pfizer Investigational Site
Bergen, Norway, 5015
Pfizer Investigational Site
Bergen, Norway, 5012
Pfizer Investigational Site
Flekkefjord, Norway, 4400
Pfizer Investigational Site
Forde, Norway, 6807
Pfizer Investigational Site
Hammerfest, Norway, 9613
Pfizer Investigational Site
Haugesund, Norway, 5500
Pfizer Investigational Site
Hobøl, Norway, 1827
Pfizer Investigational Site
Jessheim, Norway, 2050
Pfizer Investigational Site
Karasjok, Norway, 9735
Pfizer Investigational Site
Kongsberg, Norway, 3600
Pfizer Investigational Site
Kongsvinger, Norway, 2226
Pfizer Investigational Site
Kragero, Norway, 3770
Pfizer Investigational Site
Kristiansand, Norway, 4612
Pfizer Investigational Site
Kristiansund N, Norway, 6508
Pfizer Investigational Site
Larvik, Norway, 3257
Pfizer Investigational Site
Levanger, Norway, 7600
Pfizer Investigational Site
Lillestom, Norway, 2000
Pfizer Investigational Site
Lorenskog, Norway, 1478
Pfizer Investigational Site
Mo I Rana, Norway, 8607
Pfizer Investigational Site
Molde, Norway, 6407
Pfizer Investigational Site
Molde, Norway, 6415
Pfizer Investigational Site
Mosjøen, Norway, 8656
Pfizer Investigational Site
Moss, Norway, 1502
Pfizer Investigational Site
Mysen, Norway, 1850
Pfizer Investigational Site
Nesttun, Norway, 5221
Pfizer Investigational Site
Notodden, Norway, 3675
Pfizer Investigational Site
Odda, Norway, 5750
Pfizer Investigational Site
Oslo, Norway, 0913
Pfizer Investigational Site
Oslo, Norway, 0456
Pfizer Investigational Site
Oslo, Norway, 0027
Pfizer Investigational Site
Oslo, Norway, 0160
Pfizer Investigational Site
Oslo, Norway, 0514
Pfizer Investigational Site
Oslo, Norway, 0264
Pfizer Investigational Site
Oslo, Norway, 0303
Pfizer Investigational Site
Oslo, Norway, 0407
Pfizer Investigational Site
Paradis, Norway, 5231
Pfizer Investigational Site
Porsgrunn, Norway, 3922
Pfizer Investigational Site
Rud, Norway, 1309
Pfizer Investigational Site
Sandvika, Norway, 1301
Pfizer Investigational Site
Skedsmokorset, Norway, N-2020
Pfizer Investigational Site
Ski, Norway, 1400
Pfizer Investigational Site
Stavanger, Norway, 4023
Pfizer Investigational Site
Stavanger, Norway, 4004
Pfizer Investigational Site
Stavanger, Norway, 4006
Pfizer Investigational Site
Stavanger, Norway, 4095
Pfizer Investigational Site
Stord, Norway, 5400
Pfizer Investigational Site
Tansberg, Norway, 3191
Pfizer Investigational Site
Tonsberg, Norway, 3103
Pfizer Investigational Site
Trondheim, Norway, 7011
Pfizer Investigational Site
Trondheim, Norway, 7001
Pfizer Investigational Site
Tynset, Norway, 2500
Pfizer Investigational Site
Volda, Norway, 6100
Sweden
Pfizer Investigational Site
Alingsas, Sweden, 441 83
Pfizer Investigational Site
Angelholm, Sweden, 262 81
Pfizer Investigational Site
Balsta, Sweden, 746 32
Pfizer Investigational Site
Boras, Sweden, 501 82
Pfizer Investigational Site
Eksjo, Sweden, 575 81
Pfizer Investigational Site
Eskilstuna, Sweden, 631 88
Pfizer Investigational Site
Fagersta, Sweden, 737 81
Pfizer Investigational Site
Falkoping, Sweden, 521 85
Pfizer Investigational Site
Falun, Sweden, 791 82
Pfizer Investigational Site
Finspang, Sweden, 612 25
Pfizer Investigational Site
Gateborg, Sweden, 41345
Pfizer Investigational Site
Gavle, Sweden, 802 57
Pfizer Investigational Site
Gavle, Sweden, 801 87
Pfizer Investigational Site
Gavle, Sweden, 802 84
Pfizer Investigational Site
Gavle, Sweden, 800 02
Pfizer Investigational Site
Goteborg, Sweden, 413 45
Pfizer Investigational Site
Gothenburg, Sweden, 417 17
Pfizer Investigational Site
Grastorp, Sweden, 46722
Pfizer Investigational Site
Halmstad, Sweden, 301 85
Pfizer Investigational Site
Hassleholm, Sweden, 281 25
Pfizer Investigational Site
Hassleholm, Sweden, 281 31
Pfizer Investigational Site
Helsingborg, Sweden, 252 21
Pfizer Investigational Site
Helsingborg, Sweden, 252 20
Pfizer Investigational Site
Hudiksvall, Sweden, 824 81
Pfizer Investigational Site
Jonkoping, Sweden, 55185
Pfizer Investigational Site
Kalmar, Sweden, 391 85
Pfizer Investigational Site
Karlshamn, Sweden, 374 80
Pfizer Investigational Site
Karlskoga, Sweden, S-691 81
Pfizer Investigational Site
Karlskrona, Sweden, 371 85
Pfizer Investigational Site
Karlstad, Sweden, 651 85
Pfizer Investigational Site
Katarineholm, Sweden, 641 22
Pfizer Investigational Site
Koping, Sweden, 731 80
Pfizer Investigational Site
Kristinehamn, Sweden, 681 80
Pfizer Investigational Site
Lidkoping, Sweden, 531 85
Pfizer Investigational Site
Linka Ping, Sweden, 581 85
Pfizer Investigational Site
Ljungby, Sweden, 341 82
Pfizer Investigational Site
Ludvika, Sweden, 771 81
Pfizer Investigational Site
Lulea, Sweden, 971 80
Pfizer Investigational Site
Lycksele, Sweden, 921 82
Pfizer Investigational Site
Malmo, Sweden, 205 02
Pfizer Investigational Site
Malmo, Sweden, 214 22
Pfizer Investigational Site
Malmo, Sweden, 211 20
Pfizer Investigational Site
Malmo, Sweden, 211 38
Pfizer Investigational Site
Mariestad, Sweden, 542 24
Pfizer Investigational Site
Molndal, Sweden, 431 80
Pfizer Investigational Site
Motala, Sweden, 591 85
Pfizer Investigational Site
Norrkoping, Sweden, 601 82
Pfizer Investigational Site
Sala, Sweden, 733 25
Pfizer Investigational Site
Sandviken, Sweden, 811 89
Pfizer Investigational Site
Skelleftea, Sweden, 931 86
Pfizer Investigational Site
Skene, Sweden, 511 81
Pfizer Investigational Site
Skovde, Sweden, 541 85
Pfizer Investigational Site
Sodertalje, Sweden, 151 72
Pfizer Investigational Site
Stockholm, Sweden, 118 83
Pfizer Investigational Site
Stockholm, Sweden, 114 86
Pfizer Investigational Site
Stockholm, Sweden, 113 22
Pfizer Investigational Site
Stockholm, Sweden, 113 82
Pfizer Investigational Site
Stockholm, Sweden, 116 25
Pfizer Investigational Site
Stockholm, Sweden, 111 35
Pfizer Investigational Site
Stromstad, Sweden, 452 83
Pfizer Investigational Site
Uddevalla, Sweden, 451 80
Pfizer Investigational Site
Umea, Sweden, 901 85
Pfizer Investigational Site
Unknown, Sweden
Pfizer Investigational Site
Varberg, Sweden, 432 81
Pfizer Investigational Site
Vastervik, Sweden, 593 81
Pfizer Investigational Site
Vänersborg, Sweden, 46235
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00159835     History of Changes
Other Study ID Numbers: ATV-N-98-001, A2581145
Study First Received: September 8, 2005
Last Updated: September 22, 2009
Health Authority: Norway: Norwegian Medicines Agency

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases
Vascular Diseases
Simvastatin
Atorvastatin
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013